Personalis Stock Intrinsic Value – PERSONALIS Reports Fourth Quarter Earnings Results for FY2022 as of December 31, 2022 on February 23, 2023.

Earnings report

Personalis Stock Intrinsic Value – On February 23, 2023, PERSONALIS ($NASDAQ:PSNL) reported their earnings results for the fourth quarter of FY2022, as of December 31 2022. Total revenue was reported at USD -31.1 million, which represented a 53.8% decrease from the same period the previous year. Net income was reported at USD 16.7 million, which was a 19.1% decrease year over year. These results demonstrate a significant decrease in the company’s performance compared to the same period last year. Despite this decrease, PERSONALIS still managed to post a positive net income number to end the fourth quarter.

Though it is a far cry from their previous performance, their success in the midst of unprecedented economic circumstances is commendable. In addition to these results, a press release was issued detailing plans to improve their financial performance in FY2023. This includes initiatives such as cost-cutting measures, new product lines and continued investment in research and development. It is clear that PERSONALIS is taking the necessary steps to ensure successful financial results in future quarters. Investors will surely be watching closely to see if the plans are effective and have a positive impact on the company’s finances in the long run.

Stock Price

As of December 31, 2022, PERSONALIS stock opened at $3.2 and closed at $3.2 after the report was released. The results showed strong growth in the company’s revenue year-over-year, reflecting the success of its products and services. These results demonstrate the company’s commitment to delivering a positive customer experience and providing value to shareholders. Looking ahead, the company is well-positioned to continue building on its successes and delivering long-term growth. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Personalis. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Personalis. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Personalis. More…

Key Ratios Snapshot

Some of the financial key ratios for Personalis are shown below. More…

Analysis – Personalis Stock Intrinsic Value

At GoodWhale, we specialize in financial analysis of publicly traded companies. Recently, we did a deep dive on PERSONALIS and its financials. After rigorous research and analysis, we have determined that the intrinsic value of PERSONALIS shares is around $11.4. To arrive at this conclusion, we used our proprietary Valuation Line to compare its net income, debt-to-equity ratio, and its price-to-earnings ratio. The current market price of PERSONALIS stock is around $3.2, meaning the stock is currently undervalued by 71.9%. We estimate that right now is an opportune time for investors to accumulate shares of PERSONALIS for potential long-term gains. With that being said, we understand that investing should be done after careful consideration of individual investor risk tolerance and financial goals. As always, we recommend that potential investors consult with a financial advisor before making any investment decisions. More…

Peers

Personalis Inc is a leading provider of precision medicine solutions. The company offers a suite of products and services that enable its customers to develop and commercialize precision medicine therapies. The company’s products and services include genomic sequencing, bioinformatics, and clinical decision support tools. The company has a strong focus on cancer, rare disease, and pharmacogenomics. Personalis Inc has a number of competitors, including Diaceutics PLC, Charles River Laboratories International Inc, and Biodesix Inc.

– Diaceutics PLC ($LSE:DXRX)

Diaceutics PLC is a diagnostic services company. The company operates a laboratory that provides diagnostic testing services for the detection of genetic diseases. The company also manufactures and sells diagnostic kits and products. The company’s products are used by healthcare professionals in the diagnosis and treatment of genetic diseases.

– Charles River Laboratories International Inc ($NYSE:CRL)

Founded in 1947, Charles River Laboratories International, Inc. is a leading provider of drug discovery, development and manufacturing services to the global pharmaceutical and biotechnology industries. The company has helped advance the science of drug development and commercialization for over 70 years, providing services and products to support customers throughout the drug development process.

Charles River Laboratories International, Inc. has a market cap of $10.47B as of 2022 and a Return on Equity of 13.86%. The company’s market cap is a measure of its value on the stock market, and its ROE is a measure of its profitability. The company’s market cap and ROE both indicate that it is a large and profitable company.

– Biodesix Inc ($NASDAQ:BDSX)

Biodesix Inc is a biotechnology company that develops and commercializes blood-based molecular diagnostic tests for the early detection and treatment of cancer. The company’s tests are based on next-generation sequencing and machine learning.

Biodesix’s market cap is 45.58M as of 2022. The company has a Return on Equity of -655.98%. The company’s tests are based on next-generation sequencing and machine learning.

Summary

PERSONALIS, Inc. recently reported a 53.8% decrease in total revenue for the quarter, coming in at USD -31.1 million. This was accompanied by a 19.1% decrease in net income to USD 16.7 million when compared to the same period the previous year. These results could be concerning for potential investors in PERSONALIS, as they indicate that the company may be struggling financially. It is important to perform additional research and analysis before making any investment decisions.